Company: STAA
Filing Date: 2025-09-29
Form Type: DFAN14A
Source: 0001213900-25-093211
Chunk: 20

Company: STAAR SURGICAL CO
Filing Date: 2025-09-29
Form: DFAN14A
Chunk 20
---
 the Swiss company pause over STAAR’s short-term
performance and stability.

However, Broadwood highlighted that these previous challenges had now
been addressed, and that STAAR had improved its cost discipline, a resolution Broadwood now expects will lead to a “sharp rebound”
in STAAR’s revenue and profits in the coming quarters.

Bolstering these claims, Broadwood also highlighted that the results
of a clinical trial [NCT06700460] comparing Alcon’s LASIK platform to STAAR’s EVO Implantable Collamer Lens (ICL) for treating
astigmatism are soon due for publication. The shareholder said the trial results may have “significant implications” for the
competitive positioning of the EVO ICL relative to LASIK, and in turn to STAAR’s “growth prospects and strategic value”
to potential acquirers within the ophthalmic products industry.

The company said in a statement: “Broadwood is concerned that
stockholders are now being asked to accept inferior terms, despite the fact that the challenges that followed Alcon’s initial bid
have been substantially resolved.”

In closing, Broadwood reiterated that it held “serious concerns”
about the overall fairness and integrity of the sales process, stating: “In addition to the insufficient merger consideration, [the
factors at hand] lead us to believe that the acquisition is not in the best interest of STAAR’s shareholders. Accordingly, Broadwood
intends to vote against the acquisition and asks the board to immediately reconsider its recommendation thereof.”

Exhibit 7

Sep 2, 2025 7:00 AM Eastern Daylight Time

<div align='center'>Broadwood Announces Intent to Vote
Against Acquisition of STAAR Surgical by Alcon</div>

NEW YORK--(BUSINESS WIRE)--Broadwood Partners,
L.P. and its affiliates (together, “Broadwood”) currently intend to vote against the proposed acquisition of STAAR Surgical
Company by Alcon Inc. Broadwood is STAAR’s largest shareholder, owning 27.3% of STAAR’s common shares outstanding. Broadwood has owned
STAAR shares for over 30 years, has been the company’s largest shareholder since 2007, and has long been one of STAAR’s largest and most
supportive stockholders, including by providing capital to the company on various occasions. Broadwood continues to believe in the superiority
of STAAR’s proprietary technology, its large global growth potential, and its ability to again become a highly